Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Warfarin - How Good Are we at Maintaining Target Range ?

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2010 by University of Dundee.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
NHS Tayside
Information provided by:
University of Dundee
ClinicalTrials.gov Identifier:
NCT01081327
First received: March 4, 2010
Last updated: June 24, 2010
Last verified: March 2010

March 4, 2010
June 24, 2010
March 2010
March 2011   (final data collection date for primary outcome measure)
  • Bleeding Complication [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
    Any bleeding event requiring hospitalisation and / or blood transfusion. Any death attributable to bleeding i.e. Intracerebral bleed.
  • Cardiovascular outcome [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
    Ischaemic event e.g. Cerebral infarction / Myocardial infarction / death attributed to ischaemic event
Same as current
Complete list of historical versions of study NCT01081327 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Warfarin - How Good Are we at Maintaining Target Range ?
Observational Record Linkage Study Investigating Incidence of Adverse Events in Patients Anti-coagulated for Lone Atrial Fibrillation.

Patients with atrial fibrillation are often anticoagulated with Warfarin. Warfarin has a narrow therapeutic window requiring frequent monitoring. This study aims to investigate the incidence of adverse events in the "real world" for patients receiving Warfarin for lone atrial fibrillation.

Not Provided
Observational
Observational Model: Ecologic or Community
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

All patients receiving Warfarin for lone atrial fibrillation

Atrial Fibrillation
Not Provided
Patients receiving Warfarin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
5000
March 2011
March 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Prescription for Warfarin
  • Atrial Fibrillation

Exclusion Criteria:

  • Other conditions associated with increased risk of embolisation e.g. rheumatic valve disease, atrial mixoma.
  • Conditions with increased risk of bleeding.
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01081327
ELD007
No
Dr. Douglas Elder, University of Dundee
University of Dundee
NHS Tayside
Not Provided
University of Dundee
March 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP